{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(1)"],"submitter":["Sivapalan L"],"pubmed_abstract":["<h4>Background</h4>The utility of circulating tumour DNA (ctDNA) for longitudinal tumour monitoring in pancreatic ductal adenocarcinoma (PDAC) has not been explored beyond mutations in the KRAS proto-oncogene. Here, we aimed to characterise and track patient-specific somatic ctDNA variants, to assess longitudinal changes in disease burden and explore the landscape of actionable alterations.<h4>Methods</h4>We followed 3 patients with resectable disease and 4 patients with unresectable disease, including 4 patients with ≥ 3 serial follow-up samples, of whom 2 were rare long survivors (> 5 years). We performed whole exome sequencing of tumour gDNA and plasma ctDNA (n = 20) collected over a ~ 2-year period from diagnosis through treatment to death or final follow-up. Plasma from 3 chronic panc"],"journal":["BMC cancer"],"pagination":["369"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8991893"],"repository":["biostudies-literature"],"pubmed_title":["Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer."],"pmcid":["PMC8991893"],"pubmed_authors":["Chelala C","Sivapalan L","Thorn GJ","Ross-Adams H","Kocher HM","Gadaleta E"],"additional_accession":[]},"is_claimable":false,"name":"Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.","description":"<h4>Background</h4>The utility of circulating tumour DNA (ctDNA) for longitudinal tumour monitoring in pancreatic ductal adenocarcinoma (PDAC) has not been explored beyond mutations in the KRAS proto-oncogene. Here, we aimed to characterise and track patient-specific somatic ctDNA variants, to assess longitudinal changes in disease burden and explore the landscape of actionable alterations.<h4>Methods</h4>We followed 3 patients with resectable disease and 4 patients with unresectable disease, including 4 patients with ≥ 3 serial follow-up samples, of whom 2 were rare long survivors (> 5 years). We performed whole exome sequencing of tumour gDNA and plasma ctDNA (n = 20) collected over a ~ 2-year period from diagnosis through treatment to death or final follow-up. Plasma from 3 chronic panc","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-26T15:16:45.228Z","creation":"2025-04-06T14:50:32.593Z"},"accession":"S-EPMC8991893","cross_references":{"pubmed":["35392854"],"doi":["10.1186/s12885-022-09387-6"]}}